Please provide your email address to receive an email when new articles are posted on . Administering a once-yearly infusion of zoledronic acid within 90 days after the surgical repair of a low-trauma ...

Please provide your email address to receive an email when new articles are posted on . Adults with osteoporosis prescribed zoledronic acid have an increased risk for atrial fibrillation when compared ...

Zoledronic acid is effective for reducing hip fracture risk among postmenopausal women with osteoporosis. Zoledronic acid is effective for reducing hip fracture risk among postmenopausal women with ...

December 16, 2010 — Treatment with zoledronic acid (Zometa) appears to have benefits beyond bone health in patients with multiple myeloma. Researchers in the United Kingdom report that overall ...

Zoledronic acid, a bone strengthening drug, given together with chemotherapy might decrease the spread of cancer in women with locally advanced breast cancer by reducing the likelihood of tumour cells ...

Low-dose zoledronic acid appeared safe among older patients with hip fracture and advanced chronic kidney disease.

Comparison of Diameter and Perimeter Methods for Tumor Volume Calculation PURPOSE: Two identical, concurrent, parallel, multicenter, randomized, double-blind, double-dummy trials were conducted to ...

Zoledronic acid administration during the initial hospitalization for osteoporotic hip fracture significantly reduces all-cause mortality and subsequent vertebral fractures among older patients.

September 26, 2011 (Stockholm, Sweden) — Further analysis of a subgroup from the large AZURE trial shows that when zoledronic acid (Zometa) was added to chemotherapy in postmenopausal women with ...

FOLFOX for Stage II Colon Cancer? A Commentary on the Recent FDA Approval of Oxaliplatin for Adjuvant Therapy of Stage III Colon Cancer Women with bone metastases (N = 228) were randomly assigned to ...

Several clinical trials have investigated the antitumour effect of bisphosphonates when used as adjuvant treatment for early stage breast cancer. Among these, the results of the AZURE trial, although ...

(HealthDay)—Use of zoledronic acid every 12 weeks does not result in increased risk of skeletal events compared with use every four weeks among patients with bone metastases due to breast cancer, ...